According to Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) WeChat official account, the company signed an agreement with Evotec SE (hereinafter referred to as Evotec) recently, and the two sides have reached new cooperation on the exclusive authorization area of EVT201, the new drug EVT201 from China to Korea and other countries in the world.
Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) said that with the successful signing of this cooperation agreement, the company has obtained the exclusive development, production and commercialization rights of evt201 in South Korea and other countries around the world, which will expand the global scope of insomnia drug evt201, accelerate the global commercialization process of evt201 and benefit more insomnia patients. At the same time, it will further accelerate the internationalization of the company, enhance the international influence of the company and help enterprises innovate and transform. At present Zhejiang Jingxin Pharmaceutical Co.Ltd(002020) has completed evt201 clinical phase 3 trial in China and reached the primary and secondary endpoints. Meanwhile, evotec has completed clinical phase 2 trial abroad.
Data show that evt201 is a class of small molecule new drugs for the treatment of adult insomnia. Compared with existing drugs, evt201 not only has definite curative effect, but also has the characteristics of high safety, no addiction, no sleep and no need to adjust the dosage of drugs for the elderly. Evotec is a life sciences company with a unique business model focused on providing patients with efficient new therapies. As a leading drug discovery and development partner in the pharmaceutical and biotechnology industry, evotec has established a fully integrated technology platform. Through the advanced functions of this platform, evotec can provide partners with solutions, significantly improve the quality of new drugs, accelerate the drug discovery process and reduce the cost of drug research and development.
